YJ. Biotechnology Co.,Ltd.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
One-stop service for the design, construction, operation, and maintenance of micro-intelligent cell preparation facilities. YJ. Biotechnology Co.,Ltd. provides comprehensive solutions ranging from design planning, construction, and operation and maintenance to cell manufacturing technical services, meeting the clinical and commercial demands for immune cells, stem cells, exosomes, and more in a one-stop manner.
Our modular design is highly integrated with our proprietary, high-efficiency manufacturing processes. Even within standard hospital buildings, it enables cost-effective, large-scale cell production in a compact footprint, effectively reducing capital investment and project timelines.
YJ. Biotechnology Co.,Ltd. actively collaborates with domestic and international medical institutions to establish a decentralized, point-of-care cell manufacturing model. This addresses the end-to-end logistical challenges of cell products, helping healthcare institutions enhance the accessibility of cell therapies and improve the overall patient experience.
Our modular design is highly integrated with our proprietary, high-efficiency manufacturing processes. Even within standard hospital buildings, it enables cost-effective, large-scale cell production in a compact footprint, effectively reducing capital investment and project timelines.
YJ. Biotechnology Co.,Ltd. actively collaborates with domestic and international medical institutions to establish a decentralized, point-of-care cell manufacturing model. This addresses the end-to-end logistical challenges of cell products, helping healthcare institutions enhance the accessibility of cell therapies and improve the overall patient experience.
The content above was translated by Ai
Founded Year
2020
Unified Business No.
83482329
Status
Active
Number of Employees
0
Total Paid-in
Capital
201,431,340 (NT$)
Location of Company
Taiwan
, New Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
YJ. Biotechnology Co.,Ltd. was established in March 2020, with its headquarters and R&D center located in Linkou District, New Taipei City, Taiwan. With "pragmatism, professionalism, and innovative excellence" as our core corporate values, we combine Taiwan's top medical and technological strengths to lead the development of advanced cell manufacturing technologies. YJ. Biotechnology Co.,Ltd. possesses 3 key technologies and more than 12 exclusive patents. It is the first enterprise in Taiwan to independently develop a "cell pharmaceutical-grade aseptic isolator" and has become the first cell preparation unit (CPU) to obtain GTP approval from the Ministry of Health and Welfare under the Special Regulations using an aseptic isolator cell manufacturing process. Based on the PIC/S GMP-in-Design YJ intelligent cell manufacturing platform, we continue to break through the boundaries of cell manufacturing technology, providing one-stop services to meet the needs of various cells and their derivatives for treating a wide range of diseases and cancers. YJ. Biotechnology Co.,Ltd. is committed to expanding into overseas markets. Adopting a dual-engine development strategy, we actively cooperate with domestic and foreign medical institutions, academic and research institutions, and industry supply chains to promote the clinical-side decentralized cell manufacturing model, accelerate clinical trials of new drug formulations, and lead Taiwan's cell manufacturing industry to align with international standards.
The content above was translated by Ai
